ZMapp, Ebola vaccines set for testing in Liberia
This article was originally published in Scrip
Executive Summary
There's finally enough of the experimental drug ZMapp to start Phase I and II trials of the monoclonal antibody (mAb) cocktail in patients with Ebola, US officials announced on 22 January, disclosing first-time human testing of the medicine is expected to soon start in Liberia and the US.